Related Experiment Videos
New anticonvulsants in pediatrics: carbamazepine and valproate
Insights
Pediatricians can effectively manage childhood epilepsy by accurately diagnosing seizures and choosing appropriate medications. Carbamazepine and valproate offer safe and effective seizure control with fewer cognitive side effects than older drugs.
Area of Science:
- Pediatrics
- Neurology
- Clinical Pharmacology
Background:
- Epilepsy is frequently diagnosed in childhood, with pediatricians initiating long-term treatment.
- Accurate diagnosis distinguishing epilepsy from other paroxysmal disorders is crucial.
- Treatment decisions impact long-term health, cognitive function, and quality of life.
Purpose of the Study:
- To guide pediatricians in the rational selection and management of anticonvulsant medications for childhood epilepsy.
- To highlight the benefits of carbamazepine and valproate over traditional choices.
- To emphasize achieving seizure control while minimizing adverse effects.
Main Methods:
- Clinical classification of epileptic seizures based on patient history, physical examination, and EEG.
- Evaluation of medication safety and efficacy, focusing on physical tolerability and cognitive-behavioral side effects.
- Comparison of newer anticonvulsants (carbamazepine, valproate) with traditional options (phenobarbital, phenytoin).
Main Results:
- Carbamazepine and valproate are safe, well-tolerated, and less likely to cause chronic mental side effects in properly selected patients.
- These newer agents offer effective seizure control compared to phenobarbital and phenytoin.
- Pediatricians' adoption of these medications has been historically limited despite their advantages.
Conclusions:
- Pediatricians play a vital role in initiating epilepsy treatment, offering both seizure control and cognitive preservation.
- Carbamazepine and valproate represent excellent choices for pediatric epilepsy management.
- This information aims to support pediatricians in making informed treatment decisions for children with epilepsy.
Abstract:
The majority of patients with epilepsy have their first seizure during childhood and are first evaluated and diagnosed by their pediatrician. For many patients the medication selected by the pediatrician will be taken for an extended time period, perhaps even for a lifetime. The first job of the pediatrician is to be sure that the patient's recurrent attacks represent genuine epilepsy and not some other paroxysmal medical disorder such as migraine or cardiac arrhythmias. Epileptic seizures are then classified by a careful clinical description of the attacks in conjunction with the results of the physical and EEG examinations. Based on all of the information at hand, the clinician chooses the drug that is most likely to reduce or eliminate further seizures without exposing the child to unnecessary medical risk or behavioral-cognitive adverse effects. In properly selected patients, both carbamazepine and valproate are safe, physically well tolerated, and less likely to provoke chronic mental side effects than the pediatrician's "traditional" choices: phenobarbital or phenytoin. Although carbamazepine and valproate have been widely acclaimed by neurologists and epileptologists, practicing pediatricians have heretofore been less likely to initiate treatment with these drugs. Yet pediatricians have something of priceless value to offer the child with epilepsy: seizure control and a clear mind. The information in this monograph should assist the practicing pediatrician in the rational choice, initiation, and follow-up of treatment with these two excellent anticonvulsants.